These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 30446453)

  • 1. Immunohistochemical expression of Ki-67, Cyclin D1, p16INK4a, and Survivin as a predictive tool for recurrence and progression-free survival in papillary urothelial bladder cancer pTa / pT1 G2 (WHO 1973).
    March-Villalba JA; Ramos-Soler D; Soriano-Sarrió P; Hervás-Marín D; Martínez-García L; Martínez-Jabaloyas JM
    Urol Oncol; 2019 Feb; 37(2):158-165. PubMed ID: 30446453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin D1 expression in papillary superficial bladder cancer: its association with other cell cycle-associated proteins, cell proliferation and clinical outcome.
    Sgambato A; Migaldi M; Faraglia B; De Aloysio G; Ferrari P; Ardito R; De Gaetani C; Capelli G; Cittadini A; Trentini GP
    Int J Cancer; 2002 Feb; 97(5):671-8. PubMed ID: 11807796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Grade T1 Papillary Urothelial Bladder Cancer Shows Prominent Peritumoral Retraction Clefting.
    Džombeta T; Krušlin B
    Pathol Oncol Res; 2018 Jul; 24(3):567-574. PubMed ID: 28752222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
    Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
    Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
    Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK
    Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder.
    Yurakh AO; Ramos D; Calabuig-Fariñas S; López-Guerrero JA; Rubio J; Solsona E; Romanenko AM; Vozianov AF; Pellin A; Llombart-Bosch A
    Eur Urol; 2006 Sep; 50(3):506-15; discussion 515. PubMed ID: 16624482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of different p16 immunostaining methods and the prognostic role of p16/Ki-67 combined expression in non-muscle invasive bladder cancers.
    Özyalvaçli G; Özyalvaçli ME; Astarci HM; Boran Ç; Yeşil C; Üyetürk U; Aktaș G
    Pol J Pathol; 2015 Mar; 66(1):57-66. PubMed ID: 26017881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder.
    Santos LL; Amaro T; Pereira SA; Lameiras CR; Lopes P; Bento MJ; Oliveira J; Criado B; Lopes CS
    Eur J Surg Oncol; 2003 Feb; 29(1):74-80. PubMed ID: 12559081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and clinicopathologic value of ki-67 and profilin 1 immunohistochemical expression in primary pT1 urothelial bladder cancer.
    Culpan M; Turan T; Ozkanli SS; Zenginkinet T; Kazan O; Ucar T; Atis G; Caskurlu T; Yildirim A
    J Cancer Res Ther; 2021; 17(2):434-442. PubMed ID: 34121689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.
    Lotan Y; Bagrodia A; Passoni N; Rachakonda V; Kapur P; Arriaga Y; Bolenz C; Margulis V; Raj GV; Sagalowsky AI; Shariat SF
    Eur Urol; 2013 Sep; 64(3):465-71. PubMed ID: 23571005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification.
    Santos L; Amaro T; Costa C; Pereira S; Bento MJ; Lopes P; Oliveira J; Criado B; Lopes C
    Int J Cancer; 2003 Jun; 105(2):267-72. PubMed ID: 12673690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
    Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
    Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introduction and first clinical application of a simplified immunohistochemical validation system confirms prognostic impact of KI-67 and CK20 for stage T1 urothelial bladder carcinoma: single-center analysis of eight biomarkers in a series of three hundred six patients.
    Otto W; Denzinger S; Fritsche HM; Burger M; Rößler W; Bertz S; May M; Hartmann A; Hofstädter F; Wieland WF; Eder F
    Clin Genitourin Cancer; 2013 Dec; 11(4):537-44. PubMed ID: 23850551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased expression of KAI1 metastasis suppressor gene is a recurrence predictor in primary pTa and pT1 urothelial bladder carcinoma.
    Su JS; Arima K; Hasegawa M; Franco OE; Umeda Y; Yanagawa M; Sugimura Y; Kawamura J
    Int J Urol; 2004 Feb; 11(2):74-82. PubMed ID: 14706010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelial-mesenchymal transformation markers E-cadherin and survivin predict progression of stage pTa urothelial bladder carcinoma.
    Breyer J; Gierth M; Shalekenov S; Aziz A; Schäfer J; Burger M; Denzinger S; Hofstädter F; Giedl C; Otto W
    World J Urol; 2016 May; 34(5):709-16. PubMed ID: 26394624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy.
    Holmäng S; Andius P; Hedelin H; Wester K; Busch C; Johansson SL
    J Urol; 2001 Apr; 165(4):1124-8; discussion 1128-30. PubMed ID: 11257652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individual patient risk of progression of urinary bladder papillary tumors estimated from biomarkers at initial transurethral resection of bladder tumor.
    Chirife AM; Villasante N; Rojas Bilbao É; Casas G
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1709-1718. PubMed ID: 31030273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-IIα, survivin, and E-cadherin.
    Raspollini MR; Luque RJ; Menendez CL; Bollito E; Brunelli M; Martignoni G; Montironi R; Cheng L; Blanca A; Baroni G; Minervini A; Lopez-Beltran A
    Hum Pathol; 2016 Nov; 57():78-84. PubMed ID: 27473264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression of thymidine phosphorylase is a prognostic predictor for the intravesical recurrence of superficial bladder cancer.
    Nonomura N; Nakai Y; Nakayama M; Inoue H; Nishimura K; Hatanaka E; Arima R; Kishimoto T; Miki T; Kuroda H; Okuyama A
    Int J Clin Oncol; 2006 Aug; 11(4):297-302. PubMed ID: 16937303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.